Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics
21/07/2026 12:30
BRIEF-Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics July 21 (Reuters) - Akari Therapeutics PLC AKTX.O:
AKARI THERAPEUTICS ENTERS STRATEGIC RESEARCH COLLABORATION WITH WHITEHAWK THERAPEUTICS
AKARI THERAPEUTICS - CO AND WHITEHAWK TO CONDUCT PRECLINICAL STUDIES OF PH1 PAYLOAD WITH TOP1I ADC PLATFORM
AKARI THERAPEUTICS - COLLABORATION TO COMMENCE IMMEDIATELY WITH INTERIM DATA UPDATES ANTICIPATED
Source text: ID:nGNX9fWGKw
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics